Phaseline

Targets › MAPK3

MAPK3 (Mitogen-activated protein kinase 3): drug programs, companies and trials

5 programs from 4 companies in 7 trials: 4 Phase 1, 3 Phase 2; Oncology; next expected readout Dec 2026.

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. (UniProt, P27361)

Open in Phaseline: the race on MAPK3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Ulixertinib
MAP kinase ERK1 inhibitor; MAP kinase ERK2 inhibitor
MAPK3, MAPK1Phase 2Advanced Lymphoma; Advanced Malignant Solid NeoplasmDec 2026
Memorial Sloan Kettering Cancer CenterUlixertinib
MAP kinase ERK1 inhibitor; MAP kinase ERK2 inhibitor
MAPK3, MAPK1Phase 2Histiocytic Neoplasms; MyelofibrosisMay 2027
UNC Lineberger Comprehensive Cancer CenterUlixertinib
MAP kinase ERK1 inhibitor; MAP kinase ERK2 inhibitor
MAPK3, MAPK1Phase 1Tumor, SolidFeb 2028
M.D. Anderson Cancer CenterUlixertinib
MAP kinase ERK1 inhibitor; MAP kinase ERK2 inhibitor
MAPK3, MAPK1Phase 1Metastatic Colorectal CancerMar 2028
M.D. Anderson Cancer CenterTemuterkib (LY3214996)
Mitogen-activated protein kinase; ERK1/ERK2 inhibitor
MAPK3, MAPK1Phase 1Metastatic Colon AdenocarcinomaDec 2028

Conditions

Histiocytic Neoplasms (1) Myelofibrosis (1) Metastatic Colon Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Tumor, Solid (1) Advanced Lymphoma (1) Advanced Malignant Solid Neoplasm (1)

Modalities

small molecule (3), mixed (2)

Companies

M.D. Anderson Cancer Center (2) Memorial Sloan Kettering Cancer Center (1) UNC Lineberger Comprehensive Cancer Center (1) National Cancer Institute (NCI) (1)

Related targets

MAPK1 (5)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.